Jazz Pharmaceuticals Files 8-K on Financials

TL;DR

Jazz Pharma dropped an 8-K on Nov 6th detailing financial condition - check it out.

AI Summary

Jazz Pharmaceuticals plc filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing details the company's operational and financial status as of November 6, 2024.

Why It Matters

This filing provides investors with crucial updates on Jazz Pharmaceuticals' financial performance and operational status, enabling informed investment decisions.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing and does not indicate any immediate or significant risks.

Key Players & Entities

• Jazz Pharmaceuticals plc (company) — Registrant
• November 6, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.0001 — stered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Marke

Filing Documents

• jazz-20241106.htm (8-K) — 28KB
• a3q24financialpr.htm (EX-99.1) — 542KB
• jazzpharma_logoxfullcolor.jpg (GRAPHIC) — 117KB
• 0001232524-24-000084.txt ( ) — 899KB
• jazz-20241106.xsd (EX-101.SCH) — 2KB
• jazz-20241106_lab.xml (EX-101.LAB) — 23KB
• jazz-20241106_pre.xml (EX-101.PRE) — 13KB
• jazz-20241106_htm.xml (XML) — 3KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On November 6, 2024, Jazz Pharmaceuticals plc (the "Company") issued a press release (the "Press Release") announcing financial results for the Company for the quarter ended September 30, 2024. A copy of the Press Release is furnished as Exhibit 99.1 to this current report. The information in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the Press Release furnished as Exhibit 99.1 to this current report shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company whether made before or after the date hereof, regardless of any general incorporation language in such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated November 6, 2024. 104 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/ Philip L. Johnson Name: Philip L. Johnson Title: Executive Vice President and Chief Financial Officer Date: November 6, 2024

View Full Filing

View this 8-K filing on SEC EDGAR